DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder Sep 21, 2021
atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange… Sep 15, 2021
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression Sep 14, 2021
atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions Aug 12, 2021
